Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rykindo long-acting injectable risperidone in schizophrenia spectrum disorders (real-world, single-arm study)
ChiCTR2200066865Phase 4Completed
- Sponsor
- Peking University Huilongguan Hospital
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tofacitinib in Schizophrenia Spectrum and Other Psychotic Disorders (SZ), sponsored by Peking University Huilongguan Hospital. Primary endpoint: Positive and Negative Syndrome Scale (PANSS). Started Dec 2022; status: completed.
02
Drugs
03
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders (SZ)
Beyond the preview
Go deeper on ChiCTR2200066865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066865.